en
Scientific article
Open access
English

Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy

Published inJHEP Reports : Innovation in Hepatology, vol. 3, no. 3, 100279
Publication date2021
Abstract

Patients hospitalised because of mental illness often have risk factors for contracting HCV. Scaling-up HCV screening for all psychiatric inpatients as a case-detection strategy for viral elimination is underexplored. This study aimed to evaluate the cost-effectiveness of scaling-up HCV screening and treatment for psychiatry hospital admissions in Switzerland vs. the current standard-of-care risk-based approach, where only those with a history of substance misuse disorder are offered testing.

Keywords
  • Cost-effectiveness model
  • DAA, direct-acting antiviral
  • Direct-acting antiviral agents
  • Hepatitis C infection
  • ICER, Incremental cost-effectiveness ratio
  • NMB, net monetary benefit
  • PMI, patients with mental illnesses
  • PSA, probabilistic sensitivity analysis
  • Psychiatric disorder
  • QALY, quality-adjusted life-year
  • Screening strategy
  • WTP, willingness-to-pay
Citation (ISO format)
GIRARDIN, François et al. Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. In: JHEP Reports : Innovation in Hepatology, 2021, vol. 3, n° 3, p. 100279. doi: 10.1016/j.jhepr.2021.100279
Main files (2)
Article (Accepted version)
Article (Published version)
Identifiers
ISSN of the journal2589-5559
209views
74downloads

Technical informations

Creation04/27/2021 3:03:00 PM
First validation04/27/2021 3:03:00 PM
Update time03/16/2023 12:29:04 AM
Status update03/16/2023 12:29:03 AM
Last indexation02/12/2024 12:04:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack